This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Grønberg BH, Bremnes RM, Fløtten Ø, Amundsen T, Brunsvig PFr, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S.Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. Journal of Clinical Oncology 27: 3217-3224, No. 19, 1 Jul 2009
Rights and permissions
About this article
Cite this article
Pemetrexed/carboplatin for NSCLC: QOL impact assessed. Pharmacoecon. Outcomes News 581, 8 (2009). https://doi.org/10.2165/00151234-200905810-00022
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905810-00022